Consensus criteria are routinely used to clinically grade acute graft-versus-host disease (GVHD). A histologic grading system for acute GVHD is available, but there are limited data on its correlation 
| I N T R O D U C T I O N
Acute graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality in allogeneic hematopoietic cell transplantation (HCT) recipients. Despite prophylactic measures, the incidence of acute GVHD is estimated to be 30%-50% among patients with sibling donors and up to 65% in patients receiving unrelated donor transplants. 1 Treatment for established GVHD is often a challenge, with a mortality rate of 60%-80% in patients with severe acute GVHD. 2 Corticosteroids are the main-stay of treatment, however, only about 40% of patients with GVHD have a durable response to steroid therapy and there has been little improvement over the past 20 years. Grading systems, based on clinical severity, have been developed for acute GVHD and have been used to distinguish different mortality risks. [3] [4] [5] They are often used to dictate treatment decisions as well as predict treatment outcome. Recent studies have sought methods to further refine these grading systems and to further distinguish patients who may be at higher risk for treatment failure. 6, 7 A histologic grading system, proposed by Lerner in the 1970s, 8 is frequently used in the diagnosis of acute GVHD, and is based on the degree of damage to epidermal keratinocytes. Older, relatively smaller, studies failed to demonstrate a significant correlation or prognostic value between histologic findings and clinical features or outcome of GVHD, [9] [10] [11] [12] and thus there are limited data on the clinical utility of histologic grading of skin or gastrointestinal (GI) biopsies for GVHD in the recent era. Nevertheless, histologic grading remains a commonly used system by both pathologists and clinicians. We undertook this analysis to evaluate the correlation of histologic grade and clinical grade of acute GVHD in a contemporary cohort of patients that reflects the current practice of GVHD prevention and management. We also evaluated the prognostic effect of histologic GVHD grade on treatment response and outcome.
| M E T H O D S
We identified 503 consecutive patients who underwent a first alloge- episodes. In some analyses, an additional variable for histologic grade was assessed based on its relationship to clinical grade (lower, same, or higher).
We further assessed subsequent total number and type of GVHD episodes to determine if there were differences between first episodes versus subsequent/multiple episodes as well as site of GVHD episode.
Finally, we evaluated the significance of histologic grade and GVHD site within each clinical grade in univariable analysis. Analyses were performed using SAS Version 9.4 (Cary, NC). All P -values reported are 2-sided.
| R E S U LTS

| Patient and transplant characteristics
Patient, disease and transplant characteristics of 231 patients included in the analysis are shown in Table 1 
| Correlation between clinical and histologic grading
The majority of the 300 episodes of GVHD were clinical grade 1 or 2, (N 5 266, 89%, Table 2 ). Similarly, most episodes of histologic grade 3.3 | GVHD grade, treatment response, and survival outcomes Table 2 There was no difference in response or survival outcomes between patients with one versus available multiple GVHD episodes or GVHD site (data not shown); thus remaining analysis was performed only on initial GVHD episode. Information Table S1 ). This did not translate into any differences in NRM or ACM (data not shown). GVHD site was not prognostic for any outcome.
| DISCUSSION
The There are several limitations to this analysis. This was a retrospective study evaluating the grading of GVHD. Clinical staging of acute GVHD has unfortunately been found to be inconsistent and prone to errors. 15 Our institutional practice, however, is to grade GVHD prospectively and record it in our database. The histopathological diagnosis of GVHD has also been shown to be subject to substantial interindividual discrepancies; which can be improved upon with consensus among a group of pathologists. 16 Although the pathology in this study was evaluated by several different pathologists, those reading biopsies were primarily a small group which are sub-specialized within dermatopathology (for skin biopsies) and gastrointestinal pathology (for GI biopsies). This study also represents a heterogeneous population of patients, and biopsies including skin, upper, and lower GI tract.
Although we analyzed the potential effect of GVHD site (skin versus GI) in multivariable analysis, whether specific tissue site has the same Not evaluable 22 (7) 15 (6) diagnostic and prognostic value warrants further study. In addition, all patients with a diagnosis of GVHD with tissue biopsy indicating changes of acute GVHD were included. Thus, although most patients presented with acute GVHD in the first 100 days, patients who may have also had features of late acute GVHD were included. Whether an acute GVHD clinical grading system is valid in this patient population has not been well studied. Furthermore, we acknowledge that interpretation of skin and GI biopsies can be difficult and there are many overlapping features as a result of chemotherapy/radiation or other drug treatment, such as MMF. [17] [18] [19] For the purposes of this study in evaluating the utility and prognostic effect of histologic grade, we only focused on patients with clinical manifestations of GVHD whose biopsies supported this diagnosis and thus were subject to histologic grade by pathology. Regardless, in this patient population, the decision to clinically grade and treat GVHD was dependent on the clinical severity of GVHD rather than the biopsy findings. Finally, for the purposes of outcome analysis, given the heterogeneity in subsequent development or flare of GVHD and follow up biopsy availability, we only evaluated the initial GVHD biopsy episode, and thus may not fully reflect subsequent or more severe GVHD development. Despite this, we found that the histologic grade of the initial GVHD biopsy may provide prognostic information regarding treatment response and survival outcomes.
In summary, both histologic and clinical GVHD grade may be prognostic for treatment response and mortality outcomes. This study emphasizes that the use of histologic grade may help further distinguish and add prognostic information to clinical grade to guide treatment decisions and prognosis. Further study of histologic grading to further refine risk in an acute GVHD population is warranted.
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